AmeriHealth Caritas Family of Companies Medicaid Policy and Procedure

Supersedes: State-specific versions of UM.016 Policy Number: UM.016

Technology Assessment Policy

Subject: Assessment of New and Emerging Medical Treatments and Technology

Department(s): Current Effective Date: 08/2024

Last Review Date: 06/2024
Original Effective Date: 07/01/2021
Next Review Date: 08/2025

Applicable Lines of Business:

≥ 100 : Keystone First	
	☑ 7100: AmeriHealth Caritas Delaware
Pennsylvania	☑ 7200: Community HealthChoices (KFCHC,
☑ 2100: AmeriHealth Caritas Louisiana	ACPCHC)
■ 2400: Select Health of South Carolina	■ 900: AmeriHealth Caritas New Hampshire
☑ 2600: Blue Cross Complete	☑ 1200: AmeriHealth Caritas North Carolina
■ 5400/5410: AmeriHealth Caritas District of	□ 7700: AmeriHealth Caritas Ohio
Columbia	

Scope

This policy applies to the following AmeriHealth Caritas Family of Companies (ACFC) business operations.

Member is defined as enrollee, participant, recipient or beneficiary.

As necessary to comply with local state regulations, the contents of this policy may be copied into a standalone document for a specific business operation.

Purpose

To define the process used to determine inclusion of coverage of new treatments or technologies, or new uses of existing treatments or technologies, under the member's physical and behavioral health benefits.

Policy

When a request for coverage of a new technology or a new application of an existing technology is received and needs investigation, a technology assessment is conducted to determine the appropriateness of covering the requested services under the member's physical or behavioral health benefits. New technology or the new application of existing technologies relative to physical or behavioral health care includes, but is not limited to, medical procedures, behavioral healthcare procedures, medical devices, medical technologies, and pharmaceuticals.

The Clinical Policy Department is responsible for conducting formal reviews of new treatments and technologies in accordance with Policy 391.1001 *Clinical Policy Committee Policy and Procedure* and Policy CCP.1186 *Investigational Health Services*. The committee is comprised of Medical Directors and Behavioral Health Care professionals.

Requests for coverage of new treatments or technology or a new application of existing treatment or technology are reviewed by the ACFC Medical Director/Behavioral Health Medical Director using, as appropriate, some or all of the following information sources:

- State specific Medicaid Contract
- Clinical Policies
- Information from appropriate government regulatory bodies, such as the Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS) or State Health and Human Services Department
- Published scientific evidence
- Articles in peer-reviewed literature
- Recommendations from professional societies
- Publicly available reference information (including web/online resources)
- Information from a board-certified consultant/behavioral healthcare practitioner familiar with
 the specialty or technology area under review clinical information pertaining to the patient's
 medical history, current diagnosis, past treatment history and planned use of the new
 technology/new application of existing technology
- Definition of Medically Necessary as defined by state specific contract and adopted by ACFC
- EPSDT Definition of Medical Necessity for ACFC member less than 21 years of age

Definitions

N/A

See UM.001 Glossary of Terms

Procedure

- When ACFC receives a request for coverage of a new technology, or a request for a new application of an existing technology, the ACFC clinical reviewer will review per policy (UM.003 Standard and Expedited Prior Authorization of Services) and discuss with the Medical Director or Behavioral Health Medical Director.
- 2. ACFC's Medical Director/Behavioral Health Medical Director may perform a literature search and/or access a Board-Certified Specialist in the appropriate specialty to assist with the evaluation consistent with Policy UM.315 *Independent Consultant Review*.
- 3. After review of available materials, ACFC's Medical Director/Behavioral Health Medical Director will make a determination regarding medical necessity of the requested service(s). ACFC's Medical Director/Behavioral Health Medical Director will take into account as appropriate, some or all of the following information when making a decision:
 - State specific MCO Contract
 - Clinical Policies
 - Information from appropriate government regulatory bodies, such as the FDA, CMS and State Health and Human Services Department
 - Published scientific evidence

- Articles in peer-reviewed literature
- Recommendations from professional societies
- Publicly available reference information (including web/online resources)
- Information from a board-certified consultant/behavioral healthcare practitioner familiar with the specialty or technology area under review
- Clinical information pertaining to the member's medical history, current diagnosis, past treatment history and planned use of new technology/new application of existing technology.
- Definition of Medically Necessary as defined by the state specific contract regulations and adopted by ACFC
- EPSDT Definition of Medical Necessity for ACFC member less than 21 years of age
- 4. If the service is approved, a case reference number is issued and the requesting provider is notified according to Policy UM. 003 Standard and Expedited Prior Authorization of Services, and Policy UM.010 Decision Response Time.
- 5. If the service is denied, additional procedures are followed in accordance with Policy UM.017, *Notification of Adverse Benefit Determination.*
- 6. ACFC maintains documentation of research, recommendations and a determination with regard to technology assessments performed and makes them available to appropriate ACFC staff.
- 7. A request for a clinical policy from the Clinical Policy Committee can be requested electronically through processes defined by the Clinical Policy Committee.

Related Policies

See also - Policy UM.001 Glossary of Terms

See also - Policy UM.003 Standard and Expedited Prior Authorization of Services

See also - Policy UM.010 Decision Response Time

See also - Policy UM.017 Notification of Adverse Benefit Determination.

See also - Policy UM.315 Independent Consultant Review

See also - Policy CCP.1186 Investigational Health Services

See also - Policy 391.1001 Clinical Policy Committee Policy and Procedure

See also - Policy 168.235 HIPAA Privacy Definitions

See also - Policy 168.200 Authorization to Use or Disclose PHI

See also - Policy 168.212 Facsimile Machines and Transmission of Protected Health Information

See also - Policy 168.213 Safeguards to Avoid Unauthorized Use or Disclosure of Protected Health

Information, Personally Identifiable Information, and/or Certain Sensitive Demographic Data

See also - Policy 168.227 Use and Disclosure of Protected Health Information without Member Consent or Authorization

See also - Policy 591.001 Records Retention Policy & Schedule

Source Documents & References

MCO Standards for Accreditation - National Committee for Quality Assurance (NCQA), Utilization Management Standards

Attachments

A: State/Plan specific addenda < hyperling to addenda>

Approved by

Vanessa Johnson

Vice President, Utilization Management Operations

Vanissa Mjohnson

Leraye L Lawyn, M

Date: July 2, 2024

Lenaye Lawyer, MD

Vice President, Medical Affairs

Date: July 2, 2024

Revision Date	Revision	
8/2023	Annual review. No changes to the scope or intent of the policy.	
6/2024	Annual review, no changes to the scope or intent of the policy.	

AmeriHealth Caritas Family of Companies

Medicaid Policy Addendum

Territory: Louisiana Addendum Number: UM-A.016.LA

Subject: Assessment of New Medical Treatment Technology

Department(s): Utilization Management **Current Effective Date:** 11/12/2024

Last Review Date: 11/12/2023

Original Effective Date: 01/01/2023

Next Review Date: 11/2025

Service/Program	ACLA State Distinction	Reference/Source
Approval of new	AmeriHealth Caritas Louisiana (ACLA) follows new	2.4.3.2- Prohibited
technology and/or	technology assessments conducted by the Louisiana	Services
experimental	Department of Health (LDH) and all subsequent adoptions	
procedures	of new technology by LDH.	
	Any use of new technology and/or experimental	
	procedures, drugs, equipment or care is prohibited unless	
	and until approved by Secretary of LDH in writing.	

Reference/Source:

Louisiana Department of Health. Louisiana Medicaid Managed Care Organization Amendment A. Section 2.4.3.2.

Approved By:

Rodney Wise, M.D.

Market Chief Medical Officer (CMO) Signature

Date

Loretta Dumontet, MD

Lorretta Dumontet, MD

Behavioral Health Medical Director

Date

Revision Date	Revision
09/15/2022	 policy format restructured to an enterprise policy with the state specific requirements placed in an addendum
11/14/2022	 Updated contract reference 2.4.3.2
10/4/2023	 Annual review; no change to scope or content
8/20/2024	 Annual review; no changes to scope or content.